Cargando…
Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
SIMPLE SUMMARY: Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor. Despite multimodal treatment, the prognosis of GBM patients remains very poor. Oncolytic virotherapy is being evaluated as novel treatment for this patient group and clinical trials testing oncolytic viruses...
Autores principales: | Stavrakaki, Eftychia, Dirven, Clemens M. F., Lamfers, Martine L. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913874/ https://www.ncbi.nlm.nih.gov/pubmed/33557101 http://dx.doi.org/10.3390/cancers13040614 |
Ejemplares similares
-
The Multifaceted Role of Macrophages in Oncolytic Virotherapy
por: Hofman, Laura, et al.
Publicado: (2021) -
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
por: Webb, Mason J., et al.
Publicado: (2023) -
Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
por: Qi, Zhongbing, et al.
Publicado: (2022) -
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
por: Stepanenko, Aleksei A., et al.
Publicado: (2018) -
Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)